title: Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia.
abstract: Brain subjected to acute ischemic attack caused by an arterial blockage needs immediate arterial recanalization. However, restoration of cerebral blood flow can cause tissue injury, which is termed reperfusion injury. It is important to inhibit reperfusion injury to achieve greater brain protection. Because oxidative stress has been shown to activate mitogen-activated protein kinases (MAPKs), and because oxidative stress contributes to reperfusion injury, MAPK may be a potential target to inhibit reperfusion injury after brain ischemia. Here, we demonstrate that reperfusion after forebrain ischemia dramatically increases phosphorylation level of extracellular signal-regulated kinase 2 (ERK2) in the gerbil hippocampus. In addition, i.v. administration of U0126 (100-200 mg/kg), a specific inhibitor of MEK (MAPK/ERK kinase), protects the hippocampus against forebrain ischemia. Moreover, treatment with U0126 at 3 h after ischemia significantly reduces infarct volume after transient (3 h) focal cerebral ischemia in mice. This protection is accompanied by reduced phosphorylation level of ERK2, substrates for MEK, in the damaged brain areas. Furthermore, U0126 protects mouse primary cultured cortical neurons against oxygen deprivation for 9 h as well as nitric oxide toxicity. These results provide further evidence for the role of MEK/ERK activation in brain injury resulting from ischemia/reperfusion, and indicate that MEK inhibition may increase the resistance of tissue to ischemic injury.
authors.affiliation: Stroke and Brain Protection, Research Institute, and Department of Neurosurgery, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan. namura@ri.ncvc.go.jp
authors.forename: S
authors.initials: S
authors.lastname: Namura
authors.forename: K
authors.initials: K
authors.lastname: Iihara
authors.forename: S
authors.initials: S
authors.lastname: Takami
authors.forename: I
authors.initials: I
authors.lastname: Nagata
authors.forename: H
authors.initials: H
authors.lastname: Kikuchi
authors.forename: K
authors.initials: K
authors.lastname: Matsushita
authors.forename: M A
authors.initials: MA
authors.lastname: Moskowitz
authors.forename: J V
authors.initials: JV
authors.lastname: Bonventre
authors.forename: A
authors.initials: A
authors.lastname: Alessandrini
mesh_terms: D000818:Animals; D002070:Butadienes / Q000627:therapeutic use*; D002478:Cells, Cultured; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005849:Gerbillinae; D066298:In Vitro Techniques; D002546:Ischemic Attack, Transient / Q000517:prevention & control*; D048728:MAP Kinase Kinase Kinase 1; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009570:Nitriles / Q000627:therapeutic use*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D015424:Reperfusion; D013997:Time Factors
chemical_list: D002070:Butadienes; D004791:Enzyme Inhibitors; D009570:Nitriles; C113580:U 0126; D017346:Protein Serine-Threonine Kinases; D048728:MAP Kinase Kinase Kinase 1; C482578:Map3k1 protein, mouse